[¹¹C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas

Figure 2

[¹¹C]-MET PET and MRI scans of 54-year-old woman with malignant progression of grade II astrocytoma. On the left ((a), (d), and (g)), newly diagnosed left frontal-insular astrocytoma WHO grade II infiltrating the anterior portion of the corpus callosum. In the center ((b), (e), and (h)) One year later, MRI scans show increased tumor extension and compression on the left ventricular, associated with a significant increase in [¹¹C]-MET uptake, expressing malignant progression to grade III astrocytoma. On this basis, we decided to treat this patient with TMZ 200 mg/m² daily × 5 every 28 days. On the right ((c), (f), and (i)), three months after starting treatment with TMZ. MRI scans and [¹¹C]-MET PET reveal a reduction of tumor extension and compression on the left ventricular, associated with a decreased [¹¹C]-MET uptake.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)